Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

The Trust Test

- PMLiVE

BMS unveils long-term results for Opdivo in kidney cancer

Results include updated data for Opdivo with or without Yervoy

- PMLiVE

Roche’s PD-L1 inhibitor Tecentriq approved in China for SCLC

Solidifies immunotherapy drug's dominance in the setting

- PMLiVE

After FDA refusal, Takeda builds case for subcutaneous Entyvio

Intravenous Entyvio is already available in 60 countries

New strategic blueprint: the new first questions

By Thunicia Moodley

- PMLiVE

US states reject drug distributors’ opioid settlement

The Wall Street Journal reports at least 21 states want a larger settlement

- PMLiVE

Seattle Genetics wins FDA priority review for oral HER2 drug

If approved will compete with AZ/Daiichi Sankyo's Enhertu

AstraZeneca AZ

AZ revenues rise, but it says coronavirus could hit 2020

Product sales up 12% to $23.57bn for the full-year

- PMLiVE

FDA begins speedy review of BMS’ CAR-T liso-cel

Agency sets target action date of 17 August for final decision

- PMLiVE

It’s Teenage Kicks for Lucid Group

Lucid has been celebrating its 13th birthday this week. From New York to Singapore, Dubai, Macclesfield and London, teams have been gathering to celebrate the start of its teenage years.The...

Lucid Group Communications Limited

- PMLiVE

20 for 2020 – Five pharma companies to watch

As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020

EISAI

Eisai agrees to pull obesity drug Belviq after safety alert

Weight-loss drug linked to increased risk of cancer

- PMLiVE

China’s BrightGene successfully copies Gilead’s coronavirus hopeful remdesivir

Raises concerns over patent exclusivity in the country

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links